Sign up for email alert when new content gets added: Sign up
John F Burd
Lysulin, Inc., USA
Posters & Accepted Abstracts: J Food Clin Nutr
Glucose toxicity is a worldwide epidemic leading to the insulin resistance and the development of obesity and Type 2 diabetes in both children and adults. In addition to poor health and early death, this is costing our healthcare systems a fortune to treat diabetes and its complications.
Glucose is not a passive bystander in our bloodstream but is a toxic and reactive compound. Glucose reacts with all of the proteins in our body forming Glycated Proteins. These glycated proteins progress to become what is known as Advanced Glycation Endproducts (AGEs). These AGEs are known to be the culprits associated with kidney failure, blindness, amputations and cardiovascular disease. Protein glycation is also the cause of insulin resistance which can lead to insulin depletion. When this happens, we have to resort to injection of insulin in an attempt to keep our blood glucose levels in the normal range.
In over 20 years of R&D and clinical studies, nutritional supplements have been proven to combat glucose toxicity. Three important supplements having this ability are Lysine, Zinc and Vitamin C. These three supplements are now in one tablet, Lysulin® to combat glucose toxicity and protein glycation. Unlike the available prescription drugs for type 2 diabetes which are directed at the symptoms of diabetes (high blood glucose), Lysulin is directed at the problem, which is protein glycation. Clinical studies have proven that Lysulin supplementation lowers HbA1c better than most prescription drugs for diabetes.
Historically, supplements have had a bad reputation because many of them have made unsubstantiated claims. Conversely, Lysulin is firmly grounded on a foundation published literature and clinical studies proving that Lysulin will lower blood glucose and glycated proteins.
The history of studies proving the effectiveness of Lysulin will be presented along with recent data from double blind placebo-controlled studies.
John F Burd is Founder & CEO of Lysulin, Inc, and has launched an all-natural, scientifically proven nutraceutical product proven to improve the health of people with diabetes. He also founded Wonder Spray, llc., making a natural antibiotic solution useful for a variety of ailments that kills all pathogens and yet is safe and non-toxic to human tissues. Prior to Lysulin, he was a General Partner of Windamere Venture Partners. He was previously President & CEO of Dexcom, now the leader in continuing glucose monitoring for people with diabetes. He has authored over 50 publications and holds 35 patents. He graduated from Purdue University with a B.S. in Biochemistry and earned an M.S. and Ph.D., from the University of Wisconsin. In 2010, he was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
E-mail: jburd@lysulin.com
